Navigation Links
MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine
Date:9/2/2009

nd outdoor allergies," said William Berger, M.D., Clinical Professor, Division of Allergy and Immunology, University of California. "Based on demonstrated improvement in nasal allergy symptoms, ASTEPRO 0.15% is a good first-line therapy option for seasonal and perennial allergic rhinitis patients suffering with nasal symptoms."

"The approval of ASTEPRO Nasal Spray 0.15% represents a significant milestone for Meda as we continue to expand and strengthen our allergy treatment franchise," said Sharon Clarke, President and General Manager, Meda Pharmaceuticals Inc. "We are proud to introduce the first nasal antihistamine indicated for PAR and SAR with BID and QD dosing to the US market. We believe ASTEPRO Nasal Spray 0.15% can simplify the physician's treatment decision for patients with seasonal and perennial allergic rhinitis, and help patients who want rapid nasal symptom relief."

Clinical Studies

FDA approval was based primarily on the results of seven double-blind, placebo-controlled Phase III clinical trials of two to four weeks duration, and a long-term, 12-month safety trial, conducted in more than 2,300 patients with seasonal or perennial allergic rhinitis. In the SAR trials, patients were treated with 2 sprays per nostril of either ASTEPRO Nasal Spray 0.15% or placebo administered once or twice daily. In the PAR trial, patients were treated with 2 sprays per nostril of either ASTEPRO Nasal Spray 0.15% or placebo administered twice daily. Overall, results from the two- to four- week clinical trials showed that patients treated with ASTEPRO Nasal Spray 0.15% experienced a significant reduction in total nasal symptom scores (TNSS) over the entire study period compared to placebo. The TNSS consists of patient rated scores of nasal congestion, itchy nose, running nose and sneezing.

ASTEPRO Nasal Spray 0.15% demonstrated a rapid onset of nasal symptom relief in as early as 30 min
'/>"/>

SOURCE Meda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – ... innovative lymphoma research and serving the lymphoma community through ... patient services – is set to host its annual ... West Orange, NJ on June 1, 2015. Since 2010, ... programs through LRF. , This year, the Lymphoma Research ...
(Date:5/4/2015)... METTLER TOLEDO has announced an upcoming ... in a GXP Regulated Laboratory ", featuring independent ... will be presented on May 27, 2015 at ... a critical component of pharmaceutical product quality and ... recent years an increasing number of inspections have ...
(Date:5/4/2015)... OK and Seattle, WA (PRWEB) May 04, 2015 ... the formation of a collaboration to facilitate development of ... of ophthalmic disorders that lead to blindness, including Diabetic ... the MiDROPS™ formulation platform developed by EyeCRO, which can ... eye via a topical eyedrop. , Under the ...
(Date:5/4/2015)... 04, 2015 CCL, a top-ranked, global ... unique program to other leadership development consultancies. “The ... CCL and successful practitioners, expanding our capacity to drive ... said John R. Ryan, CCL President and CEO. , ... CCL Partner Network , it will schedule a one-on-one ...
(Date:5/4/2015)... New West Medicare is excited to ... to manage outpatient advanced imaging services for its members. ... its members are provided the right test at the ... with New West Medicare’s physicians and hospitals, Care to ... advanced imaging and provide an objective basis for informed ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:New West Medicare Partners with Care to Care, LLC to Manage Advanced Imaging Services 2
... LOS ANGELES, March 5 With the nation focused ... Valley) recently announced Assembly Bill 562 ( ... to businesses and consumers that have fallen victim to ... decreases health care premium costs. It requires insurance companies ...
... YORK, March 5 An article published in the ... , a joint publication of United Spinal Association ( ... Multiple Sclerosis (NARCOMS), reveals the importance of understanding ... it can also lead to a greater understanding and ...
... day for six months were able to increase the flaccid ... erectile function by up to 36%, according to an independent ... International . , Researchers from San Giovanni Battista Hospital at ... treatment could provide a viable alternative to surgery, as the ...
... Sick or injured African-American patients wait about an ... being transferred to an inpatient hospital bed following ... study published in the journal Academic Emergency ... the urgency to find equitable, cost-effective solutions to ...
... Already Breaking down Silos and Benefiting from Paperless ... Waters Corporation (NYSE: WAT ) ... strategic partnership to integrate laboratory software for improved ... Collaborating with existing common customers, Waters(R) and LabVantage(R) ...
... Texas and SAN FRANCISCO, March 5 Preferred ... payment and transaction-processing services for the health care ... ), the world,s largest retail payments network, today ... brand for PHT,s A-Claim(TM) medical payment solution for ...
Cached Medicine News:Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:United Spinal Association Report Reveals the Importance of Studying Multiple Sclerosis in Children: Developing New Insights into MS in Adults 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 2Health News:Racial disparities in emergency department length of stay point to added risks for minority patients 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 4Health News:Preferred Health Technology and Visa Inc. Team Up on Comprehensive Point-of-Service Medical Payments Solution 2Health News:Preferred Health Technology and Visa Inc. Team Up on Comprehensive Point-of-Service Medical Payments Solution 3
(Date:5/4/2015)... , May 4, 2015 PharmaEngine, Inc. ... Pharmaceuticals, Inc. (NASDAQ: MACK ) with its ... ) jointly announced that Baxter has submitted a ... Agency (EMA) for MM-398 (irinotecan liposome injection), also ... of the pancreas who have been previously treated ...
(Date:5/4/2015)... May 4, 2015  By looking at the ... distinguish between two very different conditions that can ... Henderson , MD, PhD., a Denver ... this study can help the medical ... treatment options, for Post-Traumatic Stress Disorder (PTSD) and ...
(Date:5/4/2015)... DIEGO , May 4, 2015 ... oncology company focused on the clinical development of ... data showing mitochondria-specific effects of the Company,s investigational ... enhanced anti-tumor activity when combined with a tyrosine-kinase ... found ME-344 to be a potent inhibitor of ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5
... SAN LEANDRO, Calif., Feb. 14, 2011 Mercator MedSystems, ... treating drug-resistant hypertension, announced today that Neil P. Desai, ... Desai has an extensive background in drug-delivery and global ... Prior to the acquisition of Abraxis Bioscience, Inc. (ABI), ...
... newly approved drug dabigatran is an alternative to warfarin ... atrial fibrillation, according to updated guidelines from the American ... Rhythm Society. (Logo:   http://photos.prnewswire.com/prnh/20100222/AHSALOGO ) ... Circulation: Journal of the American Heart Association, Journal ...
Cached Medicine Technology:Mercator MedSystems Appoints Neil Desai, Ph.D., to Board of Directors 2New Anti-Clotting Drug Added to Recommendations for Treating Irregular Heartbeat 2New Anti-Clotting Drug Added to Recommendations for Treating Irregular Heartbeat 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: